Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK)

Zhejiang Taimei Medical Technology Co., Ltd. provides digital solutions for life sciences research, development, and commercialization in Mainland China and internationally. The company offers Wiz.AI, an AI platform for clinical trials; TrialOS pharmaceutical R&D collaboration platform; PharmaOS, a pharmaceutical digital marketing platform; and the enterprise-medical academic interaction platform. It also provides pharmaceutical R&D solutions comprising eCollect, eBalance, eCooperate, eArchives, eImage medical imaging evaluation system, eSMS site management system, Paylite financial management system, and eCollege training management system; TrialPartner digital SMO services, IRC independent review center solutions, and eSAE clinical trial safety information management system; eSitePro clinical trial management platform, eTrialPro research ward management system, GCP-X intelligent clinical trial platform, IIT-EDC research data collection system, eScreening subject information management system, eMonitoring intelligent remote monitoring system, and IDS investigational drug services; and IDCT intelligent decentralized clinical trial. In addition, the company offers eSafety pharmacovigilance compliance management system; eSAE clinical trial safety information management system; ONECEM omni-channel marketing platform, such as ONECEM-SFE sales operation system, ONECEM-SCRM intelligent marketing system, and ONECEM-event+engagement system; and ONEInsight marketing data platform, including boundless corporate medical interaction platform. Further, it provides research and development support; technical, clinical operation, data management, statistical analysis, and management services; independent image evaluation services; and pharmaceutical marketing and institution digitalization solutions. The company was formerly known as Jiaxing Taimei Medical Technology Co., Ltd. Zhejiang Taimei Medical Technology Co., Ltd.was founded in 2013 and is headquartered in Jiaxing, China.